Dupilumab in adolescent eosinophilic esophagitis: Experience with fibrostenosis and eosinophilic gastrointestinal disease with esophageal involvement
Journal of Pediatric Gastroenterology and Nutrition · 2024-06 · 78 (6) · 1337-1341
DOI: 10.1002/jpn3.12187 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 08.04.2024. Verfasst von Robert Becker und 4 weiteren Autor:innen. Beteiligte Einrichtung: Section of Pediatric Gastroenterology, Hepatology, and Nutrition, Division of Pediatric Gastroenterology, Medical College of Wisconsin/Children's Hos…. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
We evaluated patients aged 12–20 on dupilumab 300 mg weekly for treatment of eosinophilic esophagitis (EoE) who had ≥1 follow‐up endoscopy at a tertiary care pediatric hospital ( n = 18). Fifty percent had inflammatory EoE ( n = 9), 22% had fibrostenotic EoE ( n = 4), and 28% had non‐EoE eosinophilic gastrointestinal disease (EGID) with esophageal involvement ( n = 5). Ninety‐four percent discontinued topical corticosteroids (TCS) 2–4 weeks after starting dupilumab. Eighty‐nine percent of inflammatory EoE patients had histological response (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Pediatric Gastroenterology, Hepatology, and Nutrition, Division of Pediatric Gastroenterology, Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee, Wisconsin, USA.
- Division of Pediatric Gastroenterology, Children's Hospital of Wisconsin, Milwaukee, Wisconsin, USA.
- Department of Pathology, Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee, Wisconsin, USA.
ORCID-Profile: Ankur Chugh
Förderung
- None
Zitieren
APA
Becker, R., Rigsby, M., Suchi, M., Lerner, D. G., & Chugh, A. (2024). Dupilumab in adolescent eosinophilic esophagitis: Experience with fibrostenosis and eosinophilic gastrointestinal disease with esophageal involvement. Journal of Pediatric Gastroenterology and Nutrition, 78(6), 1337-1341. https://doi.org/10.1002/jpn3.12187
Vancouver
Becker R, Rigsby M, Suchi M, Lerner DG, Chugh A. Dupilumab in adolescent eosinophilic esophagitis: Experience with fibrostenosis and eosinophilic gastrointestinal disease with esophageal involvement. Journal of Pediatric Gastroenterology and Nutrition. 2024;78(6):1337-1341. doi:10.1002/jpn3.12187
BibTeX
@article{Becker2024,
author = {Becker, Robert and Rigsby, Mariah and Suchi, Mariko and Lerner, Diana G and Chugh, Ankur},
title = {Dupilumab in adolescent eosinophilic esophagitis: Experience with fibrostenosis and eosinophilic gastrointestinal disease with esophageal involvement},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2024},
volume = {78},
number = {6},
pages = {1337--1341},
doi = {10.1002/jpn3.12187}
}
EUVIMED